Translate page

iCMLf

Alliance

    Mauro Naranie

    Panel of experts:

    Professor Michael Mauro
    Memorial Sloan Kettering Cancer Center and Weill Cornell Medicine,
    New York (USA)

    Dr Naranie Shanmuganathan
    Royal Hospital and SA Pathology,
    Adelaide (Australia)

     

    Program:
    COVID-19 and CML - an update on the CANDID data: (Michael Mauro)

    • ABL inhibition, CML and coronavirus
    • Imatinib and asciminib vs. SARS-CoV-2
    • Trials utilizing imatinib in COVID-19
    • CML and COVID-19: Uncertainty
    • The CANDID study
      • Study design
      • Geographic distribution and characteristics
      • Current treatments
      • Diagnosis and clinical history
      • COVID-19 severity
      • Impact of COVID-19 infection on CML therapy
      • Predictive factors for disease severity and survival

    COVID-19 vaccines perception in CML patients (Naranie Shanmuganathan)

    • Design of the vaccine perception study
    • Demographics of surveyed patients
    • Results from the patient perception study
      • Current TKI use
      • Sources of information re. COVID-19 vaccines
      • Patient understanding of safety and expected effectiveness
      • Patients need for more information
      • Patients willingness to get vaccinated
    • Conclusion

    Q&A Session